



Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-120001	Application No. 09/933,915
	Applicant Paul R. Odgren, <i>et al.</i>		
	Filing Date August 20, 2001	Group Art Unit 1645	

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
BD/1	AA	5,767,244	06/16/98	Goeddel <i>et al.</i>			
	AB	4,356,261	10/26/82	Kuettner			
	AC	5,786,217	07/28/98	Tubo <i>et al.</i>			
	AD	5,723,331	03/03/98	Tubo <i>et al.</i>			

RECEIVED

MAR 05 2002

TECH CENTER 1600/2900

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
	AE						Yes <input type="checkbox"/> No <input type="checkbox"/>

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
BD/1	AF	Anderson <i>et al.</i> , "Inhibition of Human Cytomegalovirus Immediate-Early Gene Expression by an Antisense Oligonucleotide Complementary to Immediate-Early RNA", <i>Antimicrob Agents Chemother</i> , 40:2004-2011, 1996.
	AG	Anderson <i>et al.</i> , "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", <i>Nature</i> , 390:175-179, 1997.
	AH	Boyan <i>et al.</i> , "Differential Expression of Phenotype by Resting Zone and Growth Region Costochondral Chondrocytes <i>In Vitro</i> ", <i>Bones</i> , 9:185-194, 1988.
	AI	Cielinski <i>et al.</i> , "Dental Abnormalities in the Osteopetrotic Rat Mutation Microphthalmia Blanc", <i>Arch. Oral Biol.</i> , 39:985-990, 1994.
	AJ	Cielinski, M.J. and Marks, S.C., Jr., "Neonatal Reductions in Osteoclast Number and Function Account for the Transient Nature of Osteopetrosis in the Rat Mutation Microphthalmia Blanc (<i>mib</i>)", <i>Bone</i> 15:707-715, 1994.
	AK	Crooke <i>et al.</i> , "Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice", <i>J. Pharmacol. Exp.</i> , 277:923-937, 1996.
	AL	Kong <i>et al.</i> , "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis", <i>Nature</i> , 397:315-323, 1999.
	AM	Kyriakides <i>et al.</i> , "Regulation of Angiogenesis and Matrix Remodeling by Localized, Matrix-Mediated Antisense Gene Delivery", <i>Mol. Ther.</i> , 3(6):842-9, 2001.
	AN	Lacey <i>et al.</i> , "Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation", <i>Cell</i> , 93:165-176, 1998.
	AO	Locksley <i>et al.</i> , "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology", <i>Cell</i> , 104(4):487-501, 2001.
	AP	Odgren <i>et al.</i> , "The <i>Toothless</i> Osteopetrotic Rat Has a Normal Vitamin D-Binding Protein-Macrophage Activating Factor (DBP-MAF) Cascade and Chondrodysplasia Resistant to Treatments With Colony Stimulating Factor-1 (CSF-1) and/or DBP-MAF", <i>Bone</i> , 25:175-181, 1999.
	AQ	Rani <i>et al.</i> , "Restoration of Normal Bone Development by Human Homologue of Collagen Type II (COL2A1) Gene in Col2a1 Null Mice", <i>Dev. Dyn.</i> , 214:26-33, 1999.
	AR	Simonet <i>et al.</i> , "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density", <i>Cell</i> , 89:309-319, 1997.

Examiner Signature <i>Bruce D. Jones</i>	Date Considered <i>11/9/05</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-120001	Application No. 09/933,915
	Applicant Paul R. Odgren, et al.		
	Filing Date August 20, 2001	Group Art Unit 1645	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
BDA	AS	Wong <i>et al.</i> , "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells", <i>J. Biol. Chem.</i> , <u>272</u> :25190-25194, 1997.					
	AT	Wong <i>et al.</i> , "TRANCE, a TNF Family Member, Activates Akt.PKB through a Signaling Complex Involving TRAF6 and c-Src", <i>Mol. Cell</i> , 4:1041-1049, 1999.					
	AU	Wraight <i>et al.</i> , "Antisense oligonucleotides in cutaneous therapy", <i>Pharmacology & Therapeutics</i> , 90:89-104, 2001.					
	AV	Yasuda <i>et al.</i> , "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL", <i>Proc. Natl. Acad. Sci. USA</i> , <u>95</u> :3597-3602, 1998.					
	AW	GenBankTM Accession No. NM_003701, "PRI date" July 17, 2001					
	AX	GenBankTM Accession No. NM_033012, "PRI date" July 17, 2001					
	AY	GenBankTM Accession No. NM_003839, "PRI date" November 1, 2000					
	AZ	GenBankTM Accession No. XM_006284, "PRI date" October 16, 2001					
	BA	GenBankTM Accession No. AF018253, "PRI date" November 22, 1997					
	BB	GenBankTM Accession No. AF019047, "PRI date" November 22, 1997					
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						
	BO						
	BP						
	BQ						

RECEIVED

MAR 05 2002

TECH CENTER 1600/2900

Examiner Signature <i>Bruce D. Davis</i>	Date Considered <i>11/9/05</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	